<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00316329</url>
  </required_header>
  <id_info>
    <org_study_id>PM_L_0164</org_study_id>
    <nct_id>NCT00316329</nct_id>
  </id_info>
  <brief_title>ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria</brief_title>
  <official_title>Multinational, Randomized, Comparative Study of the Efficacy and Safety of Three Therapeutic Regimens: Coarsucam™ (Artesunate + Amodiaquine Fixed-Dose Combination) Administered in 1 or 2 Intakes Per Day Versus Coartem® (Artemether + Lumefantrine) in the Treatment of Uncomplicated Plasmodium Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        -  To demonstrate the non-inferiority, in terms of clinical and parasitological efficacy on&#xD;
           D28 of administration of Coarsucam™ (artesunate+amodiaquine fixed-dose combination), as&#xD;
           a single daily dose, in comparison with administration of Coartem®&#xD;
           (artemether+lumefantrine).&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To compare the 3 treatment groups in terms of:&#xD;
&#xD;
        -  clinical and parasitological efficacy on D14 and D28 on the global population and on the&#xD;
           subpopulation consisting of children aged under 5 years and that for patients aged 5&#xD;
           years and over&#xD;
&#xD;
        -  clinical and laboratory safety&#xD;
&#xD;
        -  time to parasite clearance&#xD;
&#xD;
        -  time to clearance of fever&#xD;
&#xD;
        -  changes in gametocytaemia&#xD;
&#xD;
        -  impact on anaemia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and parasitological cure (after PCR correction) on D28 in compliance with WHO classification, for the Coarsucam™ &amp; Coartem® groups</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical &amp; parasitological cure (after PCR correction) on D14 &amp; D28 in the global population &amp; in the two subpopulations-Time to clearance of parasitaemia &amp; fever-Changes in gametocytaemia &amp; anaemia during follow-up- Clinical &amp; laboratory safety</measure>
  </secondary_outcome>
  <enrollment>1032</enrollment>
  <condition>Malaria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate + Amodiaquine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  adults or children weighing ≥ 10 kg&#xD;
&#xD;
          -  residing in the zone covered by the investigating centre throughout the entire&#xD;
             follow-up period&#xD;
&#xD;
          -  capable of receiving oral treatment&#xD;
&#xD;
          -  axillary temperature ≥ 37.5 degrees Celsius at the inclusion visit or history of fever&#xD;
             within the previous 24 hours&#xD;
&#xD;
          -  infection with Plasmodium falciparum, with parasite density in the blood ranging from&#xD;
             1000 to 200,000 asexual forms per cubic millimetre&#xD;
&#xD;
          -  informed consent from each participant or parents (guardians) for the children&#xD;
&#xD;
          -  negative urinary pregnancy test for all women of child-bearing age&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  presence of at least one serious or clinical danger sign of malaria: prostration,&#xD;
             consciousness disorders, recent and repeated convulsions , respiratory distress,&#xD;
             inability to drink, uncontrollable vomiting, macroscopic haemoglobinuria, jaundice,&#xD;
             haemorrhagic shock, systolic Blood Pressure &lt; 70 mmHg in adults or &lt; 50 mmHg in&#xD;
             children, spontaneous bleeding, inability to sit or stand&#xD;
&#xD;
          -  serious concomitant disease&#xD;
&#xD;
          -  allergy to one of the investigational medicinal products (drug substance or excipient)&#xD;
&#xD;
          -  pregnant women (reported, clinically visible or palpable pregnancy, or positive&#xD;
             urinary pregnancy test), or breast-feeding women&#xD;
&#xD;
          -  clinically documented heart disease (bradycardia, extrasystoles, exertional dyspnoea,&#xD;
             systolic or diastolic extrasystoles, gallop rhythm…)&#xD;
&#xD;
          -  history of hepatic and (or) haematological impairment during treatment with&#xD;
             amodiaquine&#xD;
&#xD;
          -  intake of medication metabolised by cytochrome CYP2D6 (e.g. metoprolol, flecainide,&#xD;
             imipramine, amitriptyline, clomipramine) or CYP3A4 (e.g. erythromycin, ketoconazole,&#xD;
             itraconazole, cimetidine, HIV protease inhibitors)&#xD;
&#xD;
          -  family history of congenital QTc prolongation or sudden death or another clinical&#xD;
             condition known to prolong the QTc interval&#xD;
&#xD;
          -  intake of medication known to prolong the QTc interval, such as class IA and III&#xD;
             antiarrythmics, neuroleptics, antidepressant agents, certain antibiotics including&#xD;
             drugs in the macrolide class, fluoroquinolones, imidazole and triazole, antifungal&#xD;
             agents, certain non-sedative antihistamines (terfenadine, astemizole) and cisapride&#xD;
&#xD;
          -  certain known electrolyte imbalances such as hypokalaemia or hypomagnesaemia&#xD;
&#xD;
          -  patient having received artesunate + amodiaquine or artemether + lumefantrine at a&#xD;
             suitable dosage within 30 days prior to inclusion&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Lameyre</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de santé</name>
      <address>
        <city>Tsiroanomandidy</city>
        <country>Madagascar</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bancoumana</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Keur Socé</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oussouye</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
    <country>Madagascar</country>
    <country>Mali</country>
    <country>Senegal</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>April 18, 2006</study_first_submitted>
  <study_first_submitted_qc>April 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2006</study_first_posted>
  <last_update_submitted>April 21, 2008</last_update_submitted>
  <last_update_submitted_qc>April 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Amodiaquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

